About Us

Verve Therapeutics was created with a singular focus to protect the world from heart disease

Our Mission

Verve is focused on discovering and developing therapies that safely edit the genomes of adults to confer protection against coronary artery disease, the most common type of heart disease and the leading cause of death worldwide.

Verve brings together two of the biggest breakthroughs in 21st century biomedicine — human genetic analysis and gene editing — to realize a new future, one of longevity and vitality for tens of millions of people worldwide at risk of coronary artery disease.

Verve Team

Verve has been purpose-built for the task ahead, with a founding team of world-leading experts in cardiovascular medicine and patient care, cardiovascular genetics, gene editing delivery technology and safety, drug development, and company-building.

Sekar Kathiresan, M.D.

Co-Founder and Incoming Chief Executive Officer

Kiran Musunuru, M.D., Ph.D., MPH

Co-Founder and Chief Scientific Advisor

J. Keith Joung, M.D., Ph.D.

Co-Founder

Anthony Philippakis, M.D., Ph.D.

Co-Founder and Board Member

Burt Adelman, M.D.

Co-Founder and Chairman of the Board

Barry Ticho, M.D., Ph.D.

Co-Founder and Board Member

Issi Rozen, MBA

Co-Founder and Strategic Advisor

Andrew Ashe, J.D.

President and Chief Operating Officer

David Neafus, CPA

Interim Chief Financial Officer

Andrew Bellinger, M.D., Ph.D.

Chief Medical Advisor

Robert Millman, J.D.

Intellectual Property and Business Advisor

Kallanthottathil G. Rajeev, Ph.D.

Vice President, CMC

Alexandra Chadwick, Ph.D.

Associate Director, Preclinical Research and Development

Robin Eisner

Administrative and Operations Manager

Thomas Colace, Ph.D.

Associate Principal Scientist

Jamie DeNizio, Ph.D.

Scientist

Wenjun Li

Senior Research Associate

Michael Amaonye

Research Associate

Krishna Yeshwant, M.D., MBA

Board Member

John Evans, MBA

Board Member

Jessica Alston, Ph.D.

Board Observer

Boris Nikolic, M.D.

Board Observer

Scientific Advisory Board

Eugene Braunwald, M.D.

Penny M. Heaton, M.D.

Daniel J. Rader, M.D.

Collaborations and Licensing

Verve has established foundational collaborations with industry leaders in gene editing and delivery technologies, including Beam Therapeutics and Verily. The company also has in-licensed technology from the Broad Institute and Harvard University.

Investors

Verve is supported by a top-tier syndicate of investors who share our vision for tackling the world’s most urgent health challenge.